Fast US shipping - at your door in 5-7 days/
The best prices online - go ahead and compare/
Reference-grade · >99% HPLC verified purity/
COA on every batch - mass-spec confirmed/
Pay with BTC · ETH · USDC - 10% off crypto orders/
VANTA
//Research Overview

MK-677 (Ibutamoren): Research Overview, Studied Mechanisms, and Sourcing

MK-677 (Ibutamoren, also designated MK-0677) is a non-peptide compound widely characterized in the literature as an orally bioavailable growth hormone secretagogue. This reference page summarizes how researchers have described its mechanism and the preclinical and clinical models in which it has been examined. All material is provided strictly for laboratory research and informational purposes; nothing here is a recommendation for human or animal use.

VANTA Research Desk · Updated 2026-06-19

All products are sold strictly for laboratory research purposes only. Not for human consumption, diagnostic, or therapeutic use.

What is MK-677 (Ibutamoren)?

MK-677 (Ibutamoren; developmental code MK-0677, ibutamoren mesylate) is a synthetic, non-peptide small molecule described in the literature as a spiroindoline sulfonamide. It was originally developed at Merck Research Laboratories and characterized as an orally active growth hormone (GH) secretagogue.

In published reports it is classified as a growth hormone secretagogue receptor (GHSR) ligand - that is, a mimetic of the endogenous peptide ghrelin. Researchers reference it primarily as a tool compound for studying the GH/IGF-1 axis and GHSR signaling. VANTA supplies MK-677 as a reference-grade material intended for in-vitro and laboratory research applications only. It is not a dietary supplement, food, or drug, and is not intended for human or veterinary consumption.

Studied mechanisms

In the published literature, MK-677 is described as acting on the growth hormone secretagogue receptor (GHSR), a class A G protein-coupled receptor also known as the ghrelin receptor. Mechanistic work has reported that the molecule can behave as a GHSR agonist and, in some assay systems, as a positive or negative allosteric modulator of ghrelin signaling, with downstream effects characterized in vitro including changes in inositol triphosphate (IP3) and intracellular calcium.

Across preclinical and clinical pharmacology reports, GHSR activation by MK-677 has been associated in the literature with stimulation of pulsatile GH release and corresponding changes in insulin-like growth factor 1 (IGF-1). These descriptions reflect findings reported by researchers in defined experimental settings and are presented here only as a summary of that literature.

Research models and reported findings

MK-677 has been examined across a range of preclinical and clinical research models. Early pharmacology characterized GH, IGF-1, and other hormonal responses in animal models such as beagles, and analytical work has profiled the compound and possible metabolites in equine matrices for doping-control purposes.

In human clinical research, investigators have reported on short-term (7-day) effects on 24-hour GH profiles and IGF-1 in young men, daily oral administration in elderly subjects in the context of the GH/IGF-1 axis, and changes in biochemical markers of bone turnover in elderly cohorts. A randomized trial in an Alzheimer's disease population reported no clinical effect on disease progression. These are reported research observations in specific study populations; they are summarized here for reference and do not imply any outcome, benefit, or use in any individual.

Reported research considerations

The literature surrounding MK-677 reflects an investigational compound studied under controlled conditions. Reported findings vary by model, dose, duration, and population, and several outcomes examined in trials did not reach clinical endpoints. As with any reference compound, researchers in the literature note the importance of appropriate controls and independent characterization.

VANTA does not provide dosing guidance, protocols, or any human- or animal-use instructions. Researchers are responsible for handling reference materials in accordance with applicable institutional, safety, and legal requirements for their jurisdiction and intended laboratory application.

How VANTA verifies it

Every MK-677 reference lot supplied by VANTA is subjected to analytical verification before release. Identity is confirmed by mass spectrometry (MS), and chromatographic purity is assessed by high-performance liquid chromatography (HPLC), with results reported on a per-batch Certificate of Analysis (COA).

Each COA documents the lot number, the measured purity value, and the identity confirmation so researchers can trace material to its specific batch. This per-batch verification supports reproducibility and lets laboratory users confirm that the compound matches its stated specification before it enters any research workflow. COAs are made available with the corresponding lot.

References

  1. 1.Holst et al. - Nonpeptide and peptide GH secretagogues act as ghrelin receptor agonists and allosteric modulators (mechanism); MK-677 acts as a simple agonist
  2. 2.Copinschi et al. - 7-day MK-677 effects on 24-h GH profiles, IGF-1, and adrenocortical function in normal young men
  3. 3.Chapman et al. - Stimulation of the GH-IGF-1 axis by daily oral MK-677 in healthy elderly subjects
  4. 4.Murphy et al. - Oral MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
  5. 5.Sevigny et al. - GH secretagogue MK-677: no clinical effect on AD progression in a randomized trial (Neurology, 2008)
  6. 6.Philip et al. - Characterization of GH secretagogue ibutamoren (MK-0677) and metabolites in thoroughbred horses (doping control)